Oscar Health, Inc. (OSCR) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Healthcare Plans) last closed at $31.28. The rating moved from Oversold to Overbought on August 13, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$31.28
• Last changeMoved from Oversold to Overbought on August 13, 2026
• SectorHealthcare
• IndustryHealthcare Plans

See all overbought Healthcare stocks →

AI analysis

Oscar Health is positioned as a digitally oriented insurer with structural advantages in member engagement and cost-efficient distribution. The company shows potential for continued membership expansion and margin improvement as underwriting and analytics initiatives progress. Near-term catalysts include improving loss ratios, constructive market sentiment for growth/AI names, and any positive operational updates. However, outcomes hinge on execution: regulatory scrutiny, competitive pricing pressure from large payers, and potential compliance costs are material downside risks. Monitor quarterly operating metrics (membership, medical loss ratio, and cash runway) and any regulatory developments that could change the outlook.

Key factors

• Technology-first operating model that can drive lower acquisition and servicing costs versus traditional insurers
• Membership growth potential in individual and employer segments as Oscar leverages digital engagement to expand share
• Margin improvement trajectory driven by underwriting optimization and potential AI/data analytics enhancements
• Favorable near-term market sentiment toward growth and AI that could buoy valuation multiples for digitally-enabled healthcare names
• Sufficient liquidity and access to capital versus earlier lifecycle stages (improved balance-sheet profile versus prior years)

Risks

• Regulatory and reimbursement risk for payers and digital-health intermediaries, including privacy/FTC enforcement that could raise compliance costs
• Intense competition from large national insurers and vertically integrated players (MA plans, PBMs) pressuring pricing and retention
• Execution risk on plan profitability and underwriting — continued losses or weaker-than-expected loss-ratio improvement would pressure the stock
• Macroeconomic or enrollment headwinds that reduce membership growth or increase claim severity
• Reputational or operational risks tied to data breaches, partner performance, or adverse media coverage that could depress digital engagement

Latest MarketMoodz coverage

• Raymond James Adds UNH and JANUS Living to Top Healthcare Picks2026-07-02
• Wednesday’s Analyst Calls to Watch: Nvidia, Tesla, Cava, Netflix2026-06-10

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.